Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
user
  1. Dashboard
  2. My Profile
  3. My Address
  4. My Orders
  5. Acro Membership
Login Register
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP Cytokines Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
There is no goods in the shopping cart !
My Cart|Secure Checkout
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LRRK2

LRRK2

Brief Information

Name:Leucine-rich repeat serine/threonine-protein kinase 2
Target Synonym:PARK8,LRRK2,Leucine Rich Repeat Kinase 2,Leucine-Rich Repeat Serine/Threonine-Protein Kinase 2,Parkinson Disease (Autosomal Dominant) 8,Augmented In Rheumatoid Arthritis 17,Dardarin,AURA17,RIPK7,ROCO2,Leucine-Rich Repeat Serine-Threonine Protein Kinase-2,DKFZp434H2111,FLJ45829
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:11
Lastest Research Phase:Phase 2 Clinical

Product Inquiry

* We couldn't find what you're looking for. You can let us help by filling the form below. Our tech team will get back to you shortly.
* This form is only used to collect product demand consultation. All the information will be kept strictly confidential.
Product inquiry collection form
*
*
*
*
*
*
*
*
*
ACRO Quality

Synonym Name

PARK8,Leu-rich repeat/LRR-containing protein kinase 2,Dardarin

Background

Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin and PARK8, is a kinase enzyme that in humans is encoded by the LRRK2 gene. LRRK2 is a member of the leucine-rich repeat kinase family, which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, autophagy, and vesicle trafficking. Mutations in the LRRK2 gene causes one of the most common monogenic forms of Parkinson disease (PD) . Also, several polymorphic variants in LRRK2 also modulate risk of sporadic PD.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BIIB-094 BIIB-094; ION-859; IONIS-BIIB7Rx Phase 2 Clinical Biogen Inc Parkinson Disease Details
NEU-411 NEU-411 Phase 2 Clinical Neuron23 Inc Parkinsonian Disorders; Parkinson Disease Details
DNL-151 BIIB122; DNL151; BIIB-122; DNL-151 Phase 2 Clinical Genentech Inc Parkinson Disease Details
VRN-01 VRN-01 Phase 1 Clinical Voronoi Inc Glioblastoma Details
LRRK2 Kinase Inhibitors (Oncodesign/Servier) ODS-2005294 Phase 1 Clinical Neoplasms; Parkinson Disease; Central Nervous System Diseases Details
OPM-201 OPM-201; S-221237 Phase 1 Clinical Oncodesign Biotechnology Parkinson Disease Details
ARV-102 ARV-102 Phase 1 Clinical Arvinas Inc Supranuclear Palsy, Progressive; Parkinson Disease Details
HT-4253 HT-4253 Phase 1 Clinical Halia Therapeutics Inc Alzheimer Disease Details
FB418 FB418 Phase 1 Clinical 1st Biotherapeutics Inc Parkinsonian Disorders; Parkinson Disease; Amyotrophic Lateral Sclerosis Details
WXWH0226 WXWH0226; WXWH-0226 Phase 1 Clinical Guizhou Inochini Technology Co Ltd, Wuxi Apptec Co Ltd Parkinson Disease Details
BT-0267 BT 267; BT-0267 Clinical Brenig Therapeutics Inc Parkinson Disease Details
DNL-201 DNL-201 F. Hoffmann-La Roche Ltd Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap